# FDA Inspection 1215040 - Bioreliance Corporation - August 04, 2023

Source: https://www.keypedia.com/records/fda_inspections/bioreliance-corporation/89149f6b-0201-4f3c-9500-60de669dfba4
Source feed: FDA_Inspections

> FDA Inspection 1215040 for Bioreliance Corporation on August 04, 2023. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1215040
- Company Name: Bioreliance Corporation
- Inspection Date: 2023-08-04
- Classification: No Action Indicated (NAI)
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 1295306 - 2026-01-29](https://www.keypedia.com/records/fda_inspections/bioreliance-corporation/e199758b-3727-437f-82a7-ea444bde9780)
- [FDA Inspection 1295306 - 2026-01-29](https://www.keypedia.com/records/fda_inspections/bioreliance-corporation/32d260b4-d28e-448b-869c-0c4ee6dba43c)
- [FDA Inspection 1254934 - 2024-11-22](https://www.keypedia.com/records/fda_inspections/bioreliance-corporation/7941bc6b-db19-4266-b05d-af8a19fbde51)
- [FDA Inspection 1254934 - 2024-11-22](https://www.keypedia.com/records/fda_inspections/bioreliance-corporation/effdc699-9dd4-4d58-b3a7-1c5bf7d6db8d)
- [FDA Inspection 1059115 - 2018-07-13](https://www.keypedia.com/records/fda_inspections/bioreliance-corporation/0f6693b3-da19-4b48-baba-44ef49d485ab)

Company: https://www.keypedia.com/companies/bioreliance-corporation/08d3dc20-6c7e-4f04-bb98-bbc868e70000

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c